EDTSpectral Medical Inc.

TSX · CA · Healthcare · Diagnostics & Research · spectraldx.com

1.340CAD+2.29%Mkt Cap: 286.47M $P/E: —3d ago

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activi…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap286.47M $

Enterprise Value301.76M $

Revenue (TTM)1.87M $

Gross Profit965.67K $

Net Income (TTM)-34.73M $

Revenue/Share0.0066 USD

Last Price1.340 CAD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees29

CountryCA

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)66.50

PEG—

EV/EBITDA-40.06

EV/Revenue161.29

P/S151.98

P/B-5.56

EPS (TTM)-0.12

EPS (Forward)0.02

52W Range

1.06040% of range1.760

52W High1.760 CAD

52W Low1.060 CAD

Profitability

Gross Margin54.30%

Oper. Margin-338.65%

EBITDA Margin0.00%

Profit Margin-1952.99%

ROE68.40%

ROA-781.84%

Growth

Revenue Growth-23.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-6.94M $

CapEx (TTM)142.01K $

FCF Margin467.59%

FCF Yield3.05%

Net Debt17.43M $

Net Debt/EBITDA-2.31

Balance Sheet

Debt/Equity-0.31

Current Ratio0.04

Quick Ratio0.02

Book Value/Sh-0.2390 CAD

Cash/Share0.0030 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 CAD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateDec 19, 2011

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)3.150 CAD

Upside (mean)+135.1%

Target Range2.800 CAD – 3.500 CAD

CAD2.800+135.1% to meanCAD3.500

# Analysts2

Ownership

Shares Out.293.55M

Float288.34M

Insiders17.20%

Institutions12.44%

Short Interest

Short Ratio6.7d

Short % Out.0.10%

Shares Short295.98K

Short (prev mo.)311.76K

Technical

SMA 501.370 (-2.2%)

SMA 2001.358 (-1.3%)

Beta0.21

S&P 52W Chg18.16%

Avg Vol (30d)59.72K

Avg Vol (10d)89.19K

Technical Indicators

RSI (14)43.3

MACD-0.0028

MACD Signal0.0048

MACD Hist.-0.0075

BB Upper1.435 CAD

BB Middle1.382 CAD

BB Lower1.329 CAD

BB Width7.61%

ATR (14)0.0399 CAD

Vol Ratio (20d)0.29x